ReviewAntiviral research2013
Crimean-Congo hemorrhagic fever in Iran.
Review in Antiviral research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Crimean-congo haemorrhagic fever virus in ticks and small ruminants in western Iran: epidemiological insights and genotyping.BMC infectious diseases · 2026Article
- Crimean-Congo hemorrhagic fever: An emerging threat in Europe.Virologica Sinica · 2026Review
- Crimean-congo hemorrhagic fever in Iraq, 2021-2024: epidemiological and clinical data analysis with proposed severity indicators for resource-constrained settings.BMC infectious diseases · 2026Article
- Molecular characterization and phylogenetic analysis of Crimean-Congo hemorrhagic fever virus, northwestern of Iran.BMC infectious diseases · 2025Article
- Genetic Variations in Crimean-Congo Hemorrhagic Fever Virus: Challenges for Molecular Diagnostic Assays-A Case Report.Case reports in infectious diseases · 2025Article
- Tick-Borne Diseases and Pregnancy: A Narrative Review Evaluating Pregnancy Complications Caused by Tick-Borne Diseases.Tropical medicine and infectious disease · 2024Review
- Vaccine approaches and treatment aspects against Crimean Congo hemorrhagic fever.Virusdisease · 2024Review
- A retrospective study of Crimean-Congo hemorrhagic fever in Iraq.African health sciences · 2024Article
- Crimean-Congo hemorrhagic fever, transfer patterns, vectors and history in Iran and neighboring countries.Veterinary research forum : an international quarterly journal · 2024Review
- Medically Significant Vector-Borne Viral Diseases in Iran.Microorganisms · 2023Review
- Crimean-Congo hemorrhagic fever virus in Central, Eastern, and South-eastern Asia.Virologica Sinica · 2023Review
- Large outbreak of Crimean-Congo haemorrhagic fever in Iraq, 2022.IJID regions · 2023Article
- Crimean-Congo hemorrhagic fever in the COVID-19 pandemic: A case study.Clinical case reports · 2022Article
- Spatial Distribution of Ticks (Arachniada: Argasidae and Ixodidae) and Their Infection Rate to Crimean-Congo Hemorrhagic Fever Virus in Iran.Journal of arthropod-borne diseases · 2021Article
- Genetic diversity and phylogenetic analysis of Crimean-Congo Hemorrhagic Fever viruses circulating in Pakistan during 2019.PLoS neglected tropical diseases · 2020Article
- Effect of Meteorological Factors onJournal of arthropod-borne diseases · 2019Article
- Review
- Clinical and molecular epidemiology of Crimean-Congo hemorrhagic fever in Oman.PLoS neglected tropical diseases · 2019Article
- An Emerging Biothreat: Crimean-Congo Hemorrhagic Fever Virus in Southern and Western Asia.The American journal of tropical medicine and hygiene · 2019Review
- Molecular and seroepidemiological survey on Crimean-Congo Hemorrhagic Fever Virus in Northeast of Iran.Medical journal of the Islamic Republic of Iran · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The presence of Crimean-Congo hemorrhagic fever virus (CCHFV) in Iran was first identified in studies of livestock sera and ticks in the 1970s, but the first human infection was not diagnosed until 1999. Since that time, the number of cases of CCHF in Iran has markedly increased. Through January 2012, articles in the published literature have reported a total of 870 confirmed cases, with 126 deaths, for a case fatality rate (CFR) of 17.6%. The disease has been seen in 26 of the country's 31 provinces, with the greatest number of cases in Sistan and Baluchestan, Isfahan, Fars, Tehran, Khorasan, and Khuzestan provinces. The increase in CCHF in Iran has paralleled that in neighboring Turkey, though the number of cases in Turkey has been much larger, with an overall CFR of around 5%. In this article, we review the features of CCHF in Iran, including its history, epidemiology, animal and tick reservoirs, current surveillance and control programs, diagnostic methods, clinical features and experience with ribavirin therapy, and consider possible explanations for the difference in the CFR of CCHF between Iran and Turkey. The emergence of CCHF in Iran calls for countermeasures at many levels to protect the population, but also provides opportunities for studying the epidemiology, diagnosis and management of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.